Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Fidelity Brokerage Services LLC submitted a Form 144 notice concerning Common shares that vested under a restricted stock arrangement on 06/01/2026. The filing lists a prior sale by Kelly Bliss of 26,647 Common shares on 03/02/2026 with an associated monetary figure of $136,344.70.
The record shows broker information for Fidelity at 900 Salem Street, Smithfield RI and an exchange designation of NYSE. The filing is a routine Rule 144 notice of sale related to compensation vesting.
Carlos Nueno Plana submitted a Form 144 notice relating to the proposed sale of 6,196 shares of common stock tied to a restricted stock vesting event dated 06/01/2026. The filing also lists a prior disposition of 20,165 shares on 03/02/2026 for $103,178.25.
The broker listed is Fidelity Brokerage Services LLC in Smithfield, RI. The filing identifies the shares as common stock to be sold on the New York Stock Exchange; the schedule labels the transaction as compensation (vesting). Timing and method of sale beyond these entries are not detailed in the provided excerpt.
Smith Mark Douglas reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health director Mark Douglas Smith received a grant of 30,441 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Teladoc common stock. The RSUs vest in full on the earlier of May 21, 2027 or the day immediately before Teladoc’s 2027 annual shareholder meeting.
Vested shares will be delivered to Smith upon the earliest of several events: within a specified period after separation of service, around the time of a qualifying Change of Control as defined in Teladoc’s Deferred Compensation Plan for Non-Employee Directors, or upon his death. This is a compensation-related equity award, not an open-market stock purchase or sale.
Paulus Kenneth H reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. director Kenneth H. Paulus received a grant of 30,441 restricted stock units, each representing one share of Teladoc common stock. These units vest in full on the earlier of May 21, 2027 or the day before the company’s 2027 annual stockholder meeting, with delivery of vested shares tied to separation of service, a qualifying change of control, or death.
Fenwick Sandra L reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. director Sandra L. Fenwick received a grant of 30,441 restricted stock units, each representing one share of Teladoc common stock. These RSUs vest in full on the earlier of May 21, 2027 or the day immediately before Teladoc’s 2027 annual stockholder meeting.
Vested shares will be delivered to Fenwick on the earliest of several events: within a set period after her separation of service, around a qualifying Change of Control as defined in Teladoc’s Deferred Compensation Plan for Non-Employee Directors, or upon her death.
Teladoc Health director David L. Shedlarz reported equity compensation and an award vesting event. On May 21, 2026, he received a grant of 30,441 restricted stock units (RSUs), each representing a right to one share of Teladoc common stock, vesting in full on the earlier of May 21, 2027 or the day before the 2027 annual meeting.
On May 20, 2026, he acquired 29,986 shares of common stock through an exercise or conversion of derivative securities and exercised 28,986 RSUs, fully settling that prior award. Following the stock acquisition, he directly held 61,266 common shares.
Teladoc Health director Catherine Jacobson reported routine equity compensation activity. On May 21, 2026 she received a grant of 30,441 restricted stock units, each representing one share of Teladoc common stock, vesting in full on the earlier of May 21, 2027 or the day before the 2027 annual meeting of stockholders.
On May 20, 2026 she also exercised 28,986 previously granted restricted stock units that vested in full on May 20, 2026, converting them into the same number of common shares. Following these transactions, she holds 66,853 Teladoc common shares directly and 30,441 restricted stock units.
Teladoc Health director David B. Snow, Jr. reported equity compensation-related transactions with no open-market buying or selling. He received a grant of 30,441 restricted stock units, each representing one share of Teladoc common stock, vesting in full on the earlier of May 21, 2027 or the day before the 2027 annual stockholder meeting. He also exercised 28,986 restricted stock units into an equal number of common shares, fully settling that prior RSU award. Following these transactions, he holds 113,032 shares of common stock directly and 52,000 shares indirectly through the David B. Snow, Jr. Irrevocable Trust for the benefit of his children.
Teladoc Health, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Stockholders elected all nine director nominees to serve until the 2027 annual meeting, with each receiving more votes in favor than against.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 71,154,268 votes for and 8,973,257 against. In addition, they ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 122,580,992 votes for and 1,195,800 against.
Teladoc Health Inc ownership filing reports that Vanguard Capital Management beneficially owns 9,205,306 shares of common stock, representing 5.16% of the class as disclosed for the period ending 03/31/2026. The filing lists 1,348,137 shares with sole voting power and notes dispositive power over 9,205,306 shares.